Ischemic Heart Disease
Conditions
Interventions
None listed
Sponsors
Gifu Heart Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who had received CAG and NIRS-IVUS for ACS or chronic coronary syndrome (CCS). Patients were required to have been treated with stable LLTs (including no drug medication) for at least 4 weeks before enrollment into the present study and to have an LDL-C level of more than 80 mg/dl at baseline NIRS-IVUS.
Exclusion criteria
Exclusion criteria: (i) Patients with ST-elevated myocardial infarction (ii) Chronic renal disease manifested by estimated glomerular filtration rate of less than 40 ml/min/1.73 m2 (iii) Any clinically significant abnormality identified at screening visit, physical examination, laboratory tests, or comorbidities, which, in the judgment of the investigator, would preclude safe completion of the study (to continue LLTs or perform a follow-up NIRS-IVUS).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare administration of PCSK9i with statin-medication on coronary plaque components in patients with CAD using gray-scale- and NIRS- derived measurement | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare administration of PCSK9i with statin-medication on biomarker profiles | — |
Countries
Japan
Contacts
Public ContactHideaki Ota
Gifu Heart Center Department of Cardiology
Outcome results
None listed